Videos

Prof John Chapman discusses safety data from the ODYSSEY Outcomes study

Prof Henry Ginsberg discusses the ODYSSEY Outcomes topline data

Prof Greg Schwartz Clinical implications of ODYSSEY Outcomes

Prof Greg Schwartz Key results of ODYSSEY Outcomes

Prof Greg Schwartz Rationale and design of ODYSSEY Outcomes

WOSCOPS analysis: Take home messages for clinicians

Implications from the WOSCOPS analysis

ESC/EAS Task Force issues updated clinical guidance for PCSK9 inhibitors

This Task Force from the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) has considered new evidence from cardiovascular outcomes studies with evolocumab (FOURIER) and bococizumab (now terminated), new analyses and genetic studies.t Taking account of the cost of these agents, the Task…

Treatment with evolocumab avoids the use of lipoprotein apheresis in high risk patients

Lipoprotein apheresis is an option in very high risk patients with uncontrolled LDL cholesterol levels despite maximally tolerated lipid lowering therapy. Typically, patients include those with severe familial hypercholesterolaemia (FH, inherited high cholesterol). Yet, while lipoprotein apheresis is effective in reducing LDL cholesterol there are…

ORION-1: inclisiran shows sustained LDL cholesterol lowering with 2 doses

ESC 2017: Further data from the ORION-1 trial, first reported earlier this year, showed a sustained and durable LDL cholesterol lowering response extending to Day 360 after one or two doses (1,2). Inclisiran is a novel siRNA inhibitor to PCSK9 which specifically targets intracellular PCSK9…

TAUSSIG: Evolocumab shows benefit in children with homozygous familial hypercholesterolaemia

ESC Congress 2017: First data in children with homozygous familial hypercholesterolaemia (FH, inherited high cholesterol) aged from 12 years show that evolocumab is an effective option, added to statin and ezetimibe with or without lipoprotein apheresis (1). Homozygous FH is a rare genetic disorder characterised…

Will CANTOS and REVEAL change how we view the clinical use of PCSK9 inhibitors?

Prof Anthony Wierzbicki, New Associate Editor of PCSK9 Forum discusses Atherosclerosis has long been recognised as a chronic inflammatory disease, where low-density lipoproteins (LDL) interact with both innate and adaptive immunity mechanisms. However, while inflammatory infiltration by circulating white blood cells is an important part…

VIDEO: Implications of very low LDL cholesterol levels

One of the key concerns of clinicians in the aftermath of FOURIER is the safety of very low LDL cholesterol levels. This is underlined by the fact that 42% of patients on evolocumab in FOURIER attained LDL cholesterol levels ≤25 mg/dl (0.65 mmol/L).(1) As previously…

How does statin intolerance impact on clinical outcome?

Professor Robert Rosenson (Mount Sinai Heart, Icahn School of Medicine, New York) discusses.

How to diagnose statin intolerance?

Professor Robert Rosenson (Mount Sinai Heart, Icahn School of Medicine, New York) discusses.

Dr Peter Lansberg: What does FOURIER mean for FH patients?

PCSK9 Forum News Editor, Dr Peter Lansberg (Academic Medical Center, Amsterdam, the Netherlands) discusses what the landmark results of FOURIER and SPIRE-2 will mean for the management of patients with familial hypercholesterolaemia (FH, inherited high cholesterol). SPIRE-2 is clearly relevant given that this study also…

The Word from ACC 2017 – Implications for Practice

The highlight of ACC 2017 was the FOURIER trial, representing the culmination of the PCSK9 revolution. Here PCSK9 Forum Co-Editor Professor John Chapman and experts from the PCSK9 Forum Editorial Board discuss implications from FOURIER for clinical practice.

The Word from ACC 2017 – Key Results

The highlight of ACC 2017 was the FOURIER trial, representing the culmination of the PCSK9 revolution. Here PCSK9 Forum Co-Editor Professor John Chapman and experts from the PCSK9 Forum Editorial Board dissect the key results and messages from FOURIER.

VIDEO: Access to PCSK9 inhibitor treatment: NLA survey provides important pointers

Professor Dean G. Karalis (Director of Preventive Cardiology, Pennsylvania Hospital, USA) discusses the issues and how to counter these. FOURIER and SPIRE-2 have clearly shown the benefits of lowering LDL cholesterol beyond current targets in very high risk patients. However, from a routine practice view,…

FOURIER in the Hot Seat: What are the Implications for practice and access?

FOURIER was a landmark trial for PCSK9 inhibition, showing significant reduction in cardiovascular events with evolocumab in very high risk patients on maximally tolerated lipid lowering therapy. The results from FOURIER, together with those from SPIRE-2 in patients at higher baseline LDL cholesterol levels, clearly…